SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

Part 1A is a dose escalation study in patients with small cell lung cancer or large cell
neuroendocrine carcinoma with cytologically confirmed, limited or extensive SCLC or LCNEC
that have relapsed or refractory limited or extensive disease following no more than 2 prior
chemotherapy regimens.

Part 1B is an expansion study where patients will be enrolled and treated in order to further
characterize safety and preliminary efficacy in patients with SCLC or LCNEC and further
characterize PK, immunogenicity and target expression and possible relationship to clinical
outcome.

Inclusion Criteria:

- Histologically or cytologically confirmed SCLC (either limited or extensive disease)
or LCNEC, that has relapsed from the most current treatment or was refractory to
treatment

- Evidence of progressive disease during or following no more than 2 prior chemotherapy
regimens

- Measurable disease as defined by RECIST

- ECOG performance status of 0 or 1

- Adequate hematological and organ function as confirmed by laboratory values

- Treatment with anticancer/investigational drugs, therapy ≤ 4 weeks prior to first dose
of SC-002

Exclusion Criteria:

- Active central nervous system metastases

- Uncontrolled cardiac disease

- Positive serology for hepatitis B or hepatitis C or known HIV infection

- Presence of any condition that may increase the risks associated with study
participation and interfere with the interpretation of study results